中文 | English
Return
Total: 7 , 1/1
Show Home Prev Next End page: GO
MeSH:(Antineoplastic Agents, Immunological/adverse effects*)

1.Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case.

Feng XU ; Zhu SHEN ; Hong TAO ; Zhu ZHU ; Jia-Long TAO ; Zheng-Yang FENG

Acta Academiae Medicinae Sinicae 2023;45(2):351-354

3.Clinical and pathological characteristics of immune-mediated liver injury caused by immune checkpoint inhibitors.

Yan Lin ZENG ; Yuan LI ; Hao TANG ; Yan XU ; Min Jiang CHEN ; Yue LI ; Meng Zhao WANG ; Bei TAN ; Jia Ming QIAN

Chinese Journal of Internal Medicine 2023;62(6):700-704

4.Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer.

Yi Cen YING ; Qi TANG ; Kai Wei YANG ; Yue MI ; Yu FAN ; Wei YU ; Yi SONG ; Zhi Song HE ; Li Qun ZHOU ; Xue Song LI

Journal of Peking University(Health Sciences) 2022;54(4):644-651

5.Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.

Yingyan YU

Frontiers of Medicine 2018;12(2):229-235

6.A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients.

Shaohua CUI ; Xiaoxiao GE ; Xiangyang LI

Chinese Journal of Lung Cancer 2023;26(4):257-264

7.Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer.

Chinese Journal of Oncology 2022;44(9):913-927

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 7 , 1/1 Show Home Prev Next End page: GO